Welcome to our dedicated page for United-Guardian news (Ticker: UG), a resource for investors and traders seeking the latest updates and insights on United-Guardian stock.
Founded in 1942, United-Guardian, Inc. (symbol: UG) stands as a reputable entity in the domains of cosmetic ingredients, pharmaceuticals, medical products, and specialty industrial products. With a rich history spanning over seven decades, the company has established a robust presence through a global network of marketing partners, catering to most of the leading names in the global cosmetic industry.
United-Guardian's flagship product line includes an extensive array of water-based moisturizing and lubricating gels, which serve dual purposes in both cosmetic and medical applications. These products underscore the company's commitment to innovation and efficacy, ensuring high standards of quality and utility.
The product portfolio features renowned names such as Klensoft, Deselex, Renacidin, and Lubrajel Fluid. Klensoft and Deselex are pivotal in the cosmetic segment, enhancing product formulations with their unique properties. Renacidin, a key pharmaceutical product, and Lubrajel Fluid, known for its superior lubricating properties, demonstrate the company's versatile research and development capabilities.
United-Guardian markets its pharmaceutical products through full-line drug wholesalers across the United States, ensuring widespread availability. The medical and specialty industrial products are distributed directly to end-users or through contract manufacturers, highlighting a strategic approach to reach diverse markets.
With a focus on four distinct product categories - cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness - the company continually drives research and development to stay ahead in these competitive fields. The majority of the revenue is generated from sales within the U.S., reflecting a strong domestic market presence.
For more detailed financial information and the latest updates, visit the company’s official website at www.u-g.com.
United-Guardian reported increased financial results for Q3 and the first nine months of 2024. Nine-month sales grew from $8.28M to $9.71M, with net income rising from $1.84M ($0.40/share) to $2.75M ($0.60/share). Q3 sales remained stable at $3.06M, while net income increased from $627K ($0.14/share) to $865K ($0.19/share). Cosmetic ingredients sales rose 8% in Q3 and 68% in the first nine months. Medical lubricants saw a 2% Q3 decrease but 4% nine-month growth. Pharmaceutical sales declined 6% in Q3 and 11% over nine months due to a Renacidin® supply disruption.
United-Guardian (NASDAQ:UG) reported strong financial results for Q2 and H1 2024. Sales for H1 2024 increased to $6,645,149 from $5,220,623 in 2023, while net income rose to $1,881,667 ($0.41 per share) from $1,217,175 ($0.26 per share). Q2 2024 sales grew to $3,390,205 from $2,650,299 in 2023, with net income increasing to $956,225 ($0.21 per share) from $461,094 ($0.10 per share).
Key highlights include:
- Cosmetic ingredient sales up 84% in Q2 and 115% in H1 2024
- Medical lubricant sales increased 15% in Q2 and 9% in H1 2024
- Pharmaceutical product sales up 3% in Q2 but down 13% in H1 2024 due to a temporary shutdown
The company attributes the growth to increased purchases from its largest cosmetic distributor and recovering Renacidin® sales after production resumed in late March.
United-Guardian (NASDAQ: UG) announced a cash dividend of $0.35 per share, payable on July 31, 2024, to stockholders of record as of July 23, 2024. This marks the 29th consecutive year of dividend payments by the company.
The dividend represents a 40% increase over the $0.25 per share paid earlier this year and a 250% increase over the $0.10 dividend paid last July. President Donna Vigilante emphasized the balance between supporting growth initiatives and providing strong dividends to stockholders.
United-Guardian manufactures cosmetic ingredients, medical lubricants, sexual wellness ingredients, and pharmaceuticals.
United-Guardian (NASDAQ:UG) announced the hiring of Denise Costrini as the new marketing director. Ms. Costrini brings over 25 years of experience in the personal care and specialty chemicals industries. She holds a Bachelor of Science degree in Industrial and Operations Engineering and has expertise in strategic market planning and new product commercialization. The company believes her background in market assessment, brand positioning, and new business development will enhance market penetration and international growth, particularly in areas with significant expansion opportunities.
United-Guardian, Inc. (NASDAQ:UG) reported increased first quarter sales and earnings for 2024. Sales rose from $2,570,324 in 2023 to $3,254,944 in 2024, with net income increasing from $756,081 to $925,442. Cosmetic ingredients sales surged by 146%, driven by increased purchases from their largest distributor, ASI. However, pharmaceutical sales declined by 30% due to a temporary shutdown at a contract manufacturer's facility affecting Renacidin® sales. Production has since resumed, and orders are being fulfilled since March.
FAQ
What is the current stock price of United-Guardian (UG)?
What is the market cap of United-Guardian (UG)?
What does United-Guardian, Inc. specialize in?
When was United-Guardian, Inc. founded?
What are some key products of United-Guardian, Inc.?
How are United-Guardian's pharmaceutical products distributed?
What is the significance of water-based gels in United-Guardian's product line?
Which markets does United-Guardian primarily serve?
How does United-Guardian distribute its medical and specialty industrial products?
Where can I find more financial information about United-Guardian, Inc.?
What are the main product categories of United-Guardian?
Does United-Guardian conduct research and development?
